Company News
First Approval of Synthetic Liraglutide in China: Hybio Achieves a Full-Chain Breakthrough
A landmark GLP-1 milestone connects Hybio's peptide API, finished dosage form, quality, and commercialization capabilities.
Hybio Pharmaceutical has reached two important milestones in its liraglutide program, reinforcing a vertically integrated capability that spans peptide active ingredient development and finished dosage form execution.
The progress reflects a long-term focus on peptide process science, formulation development, quality systems, and global registration strategy.
A connected GLP-1 platform
By maintaining scientific and manufacturing knowledge across the API and formulation pathway, Hybio can reduce handoffs and strengthen control of critical quality attributes.
This connected model supports reliable scale-up while creating a stronger foundation for future metabolic-health programs.
From milestone to broader access
The company will continue to advance international registration, supply readiness, and lifecycle development around its peptide portfolio.
